Use of statins and gemfibrozil in patients with type 2 diabetes mellitus and cardiovascular risk factors attending adult day health care centers: An opportunity for pharmacists

Consultant Pharmacist

Volumn 22, Issue 1, 2007, Pages 38-44

  Rosenberg, Jack M ^a,b   Zerilli, Tina ^a,b   Nathan, Joseph P ^b   Mcguire, Howard ^b,c  

^a International Drug Information Center   (United States)

^b LONG ISLAND UNIVERSITY   (United States)

^c Department of Psychology and Biostatistics ^*

Author keywords

ACP Guidelines; Gemfibrozil; Statins; Type 2 Diabetes; Underutilization

Indexed keywords

ATORVASTATIN; GEMFIBROZIL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; STATINE DERIVATIVE;

ADULT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DOSE RESPONSE; HEALTH CENTER; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACIST; PRESCRIPTION; RETROSPECTIVE STUDY; REVIEW; SYSTEMATIC REVIEW; UNITED STATES;

EID: 33846427337     PISSN: 08885109     EISSN: None     Source Type: Journal    
DOI: 10.4140/TCP.n.2007.38     Document Type: Review

References (25)

1. American Diabetes Association. National Diabetes Fact Sheet, 2005. http://www.Diabetes.Org/Uedocuments/Nationaldiabetesfactsheetrev.pdf. Accessed April 25, 2006.
2. American Diabetes Association. Direct and indirect costs of diabetes in the United States. http://www.Diabetes.Org/Diabetes-Statistics/Cost-Of-Diabetes- In-Us.Jsp. Accessed April 25, 2006.
3. Voelker R. Widespread statin use recommended for patients with type 2 diabetes. JAMA 2004;291:2419-20.
4. Snow V, Aronson MD, Hornbake ER et al., for the Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Lipid control in the management of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2004;140:644-9.
5. Stamm PL, Kelley KW, Donaldson AR. Minimizing cardiovascular morbidity and mortality in patients with type 2 diabetes mellitus: a literature review. Adv Pharm 2005;3:23-50.
6. American Diabetes Association. Dyslipidemia management in adults with diabetes. Diabetes Care 2004;27(suppl 1):S68-S71.
7. Vijan S, Hayward RA. Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Ann Intern Med 2004;140:650-8.
8. O'Neil J. Vital signs: treatments; statins and diabetes: new advice. NY Times April 20, 2004.
9. Grundy SM, Cleeman JI, Bairey Merz CN et al., for the coordinating committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004;110:227-39.
10. Colhoun HM, Betteridge DJ, Durrington PN et al., for the CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96.
11. Heart Protection Study Collaborative Group. MRC/BHF Heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16.
12. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2005;28(suppl 1):S4-S36.
13. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins. Lancet 2005;366: 1267-78.
14. Ma J, Sehgal NL, Ayanian JZ et al. National trends in statin use by coronary heart disease risk category. PLoS Med [Serial Online] 2005;2:E123.
15. McFarlane SI, Jacober SJ, Winer N et al. Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. Diabetes Care 2002;25:718-23.
16. Kennedy AG, Maclean CD, Littenberg B et al. The challenge of achieving national cholesterol goals in patients with diabetes. Diabetes Care 2005;28:1029-34.
17. Tonstad S, Rosvold EO, Furu K et al. Undertreatment and overtreatment with statins: the Oslo Health Study 2000-2001. J Intern Med 2004;255:494-502.
18. Brown LC, Johnson JA, Majumdar SR et al. Evidence of suboptimal management of cardiovascular risk in patients with type 2 diabetes mellitus and symptomatic atherosclerosis. CMAJ 2004;171:1189-92.
19. Bennett KE, Williams D, Feely J. Under-prescribing of cardiovascular therapies for diabetes in primary care. Eur J Clin Pharmacol 2003;58:835-41.
20. New York State Department of State. Division of Administrative Rules. 2003 Register. http://www.Dos.State.Ny.Us/Info/Register/2003/Oct8/Pdfs/Rules. pdf. Accessed October 31, 2005.
21. Drug Facts and Comparisons. Drug Facts and Comparisons 4,0 [Online]. 2005. Available from Wolters Kluwer Health, Inc. Accessed October 31, 2005.
22. Sotiriou CG, Cheng JW. Beneficial effects of statins in coronary artery disease-beyond lowering cholesterol. Ann Pharmacother 2000;34:1432-9.
23. McEvoy GK. AHFS Drug Information 2006. Bethesda, MD: American Society of Health-System Pharmacists, Inc.; 2006:1674.
24. Cranor CW, Bunting BA, Christensen DB. The Asheville Project: long-term clinical and economic outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc 2003;43:173-84.
25. McCord AD. Clinical impact of a pharmacist-managed diabetes mellitus drug therapy management service. Pharmacotherapy 2006;26:248-53.